Octapharma
Octapharma AG, headquartered in Switzerland (CH), is a leading global player in the biopharmaceutical industry, specialising in the development and production of human proteins derived from human plasma and recombinant technologies. Founded in 1983, Octapharma has established a strong presence in Europe, North America, and Asia, with a commitment to innovation and quality. The company’s core product offerings include a range of immunoglobulins, coagulation factors, and albumin, which are essential for treating various medical conditions, including immune deficiencies and bleeding disorders. Octapharma is renowned for its dedication to patient safety and product efficacy, setting it apart in a competitive market. With a robust pipeline and a focus on research and development, Octapharma has achieved significant milestones, positioning itself as a trusted name in the biopharmaceutical sector, committed to improving patient outcomes worldwide.
DitchCarbon Score
How does Octapharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Octapharma's score of 30 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Octapharma's reported carbon emissions
In 2023, Octapharma reported total carbon emissions of 177,000 kg CO2e in Great Britain, with Scope 1 emissions at 102,000 kg CO2e, Scope 2 at 4,000 kg CO2e, and Scope 3 at 71,000 kg CO2e. This marks a significant reduction from their 2019 emissions of 228,000 kg CO2e, representing a 22% decrease over the four-year period. The company aims to achieve a further 30% reduction in emissions by 2028. Globally, Octapharma's emissions in 2022 were recorded at 181,000 kg CO2e, with Scope 1 emissions at 80,000 kg CO2e, Scope 2 at 7,000 kg CO2e, and Scope 3 at 94,000 kg CO2e. The company has set a long-term commitment to reach Net Zero emissions by 2050, encompassing all scopes of emissions. These initiatives reflect Octapharma's dedication to sustainability and climate responsibility, aligning with industry standards for reducing carbon footprints.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2022 | |
|---|---|---|
| Scope 1 | 73,000 | 00,000 |
| Scope 2 | 7,000 | 0,000 |
| Scope 3 | 156,000 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Octapharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
